Pre-exposure prophylaxis (PrEP) has been recommended by the U.S. Preventive Services Task Force for people at high risk of contracting HIV. New therapies have expanded options for patients and providers. However, recently implemented formulary restrictions may have affected patient access. This white paper studies the impact of formulary restrictions on “walk-away” rates for commercially insured patients prescribed HIV PrEP.
This paper was commissioned by Gilead Sciences Inc.